21
Jan

BioMarin is taking a flyer on HDAC inhibitors, taking up Repligen’s portfolio in exchange for as much as $162 million and adding candidates in Friedreich’s ataxia and other neurological disorders.

…read more

Source: BioMarin trades up to $162M for Repligen’s stable of HDAC inhibitors

    

0 No comments